Tracleer (Bosentan) for Pulmonary Hypertension | myPHteam

Connect with others who understand.

sign up Log in
About myPHteam
Powered By

Tracleer is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity and limit disease progression in adults with pulmonary arterial hypertension (PAH). Tracleer is also approved to treat children over 3 years old with idiopathic or congenital PAH. Tracleer may be referred to by its drug name, bosentan.

Tracleer is an endothelin receptor antagonist. Endothelin is a substance made by the body that causes the blood vessels to constrict. Endothelin receptor antagonists are believed to work by limiting the amount of endothelin in the blood. In cases of PAH, endothelin receptor antagonists may slow disease progression and potentially reverse some heart and lung damage caused by the disease.

How do I take it?
Prescribing information states that Tracleer is taken orally twice daily. Due to its ability to cause severe birth defects, Tracleer is only available through a limited distribution program called Tracleer Risk Evaluation and Mitigation Strategies (REMS) Program.

Tracleer comes in tablet form.

Side effects
The FDA-approved label for Tracleer lists common side effects including respiratory tract infections, fever, and anemia.

Rare but serious side effects listed for Tracleer include liver failure, severe birth defects, severe fluid retention, pulmonary edema (fluid in the lungs), blood disorders, and decreased sperm count.

For more details about this treatment, visit:

Tracleer — Actelion

Endothelin receptor antagonists — Pulmonary Hypertension Association UK

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in